These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 26417924)

  • 1. Thioredoxins in cardiovascular disease.
    Whayne TF; Parinandi N; Maulik N
    Can J Physiol Pharmacol; 2015 Nov; 93(11):903-11. PubMed ID: 26417924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The thioredoxin antioxidant system.
    Lu J; Holmgren A
    Free Radic Biol Med; 2014 Jan; 66():75-87. PubMed ID: 23899494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A thioredoxin reductase and/or thioredoxin system-based mechanism for antioxidant effects of ambroxol.
    Huang J; Xu J; Tian L; Zhong L
    Biochimie; 2014 Feb; 97():92-103. PubMed ID: 24103200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity assays of mammalian thioredoxin and thioredoxin reductase: fluorescent disulfide substrates, mechanisms, and use with tissue samples.
    Montano SJ; Lu J; Gustafsson TN; Holmgren A
    Anal Biochem; 2014 Mar; 449():139-46. PubMed ID: 24374250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thioredoxin in vascular biology: role in hypertension.
    Ebrahimian T; Touyz RM
    Antioxid Redox Signal; 2008 Jun; 10(6):1127-36. PubMed ID: 18315495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thioredoxin system in cell death progression.
    Lu J; Holmgren A
    Antioxid Redox Signal; 2012 Dec; 17(12):1738-47. PubMed ID: 22530689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thioredoxin-interacting protein: pathophysiology and emerging pharmacotherapeutics in cardiovascular disease and diabetes.
    Chong CR; Chan WP; Nguyen TH; Liu S; Procter NE; Ngo DT; Sverdlov AL; Chirkov YY; Horowitz JD
    Cardiovasc Drugs Ther; 2014 Aug; 28(4):347-60. PubMed ID: 25088927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy.
    Tonissen KF; Di Trapani G
    Mol Nutr Food Res; 2009 Jan; 53(1):87-103. PubMed ID: 18979503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of thioredoxin in lung disease.
    Xu J; Li T; Wu H; Xu T
    Pulm Pharmacol Ther; 2012 Apr; 25(2):154-62. PubMed ID: 22293327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased thioredoxin levels are related to insulin resistance in familial combined hyperlipidaemia.
    Martinez-Hervas S; Artero A; Martinez-Ibañez J; Tormos MC; Gonzalez-Navarro H; Priego A; Martinez-Valls JF; Saez GT; Real JT; Carmena R; Ascaso JF
    Eur J Clin Invest; 2016 Jul; 46(7):636-42. PubMed ID: 27208733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The thioredoxin system and cancer therapy: a review.
    Mohammadi F; Soltani A; Ghahremanloo A; Javid H; Hashemy SI
    Cancer Chemother Pharmacol; 2019 Nov; 84(5):925-935. PubMed ID: 31367788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High redox thioredoxin but low thioredoxin reductase activities in the serum of patients with rheumatoid arthritis.
    Lemarechal H; Allanore Y; Chenevier-Gobeaux C; Ekindjian OG; Kahan A; Borderie D
    Clin Chim Acta; 2006 May; 367(1-2):156-61. PubMed ID: 16458876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased serum levels of thioredoxin in patients with coronary artery disease plus hyperhomocysteinemia is strongly associated with the disease severity.
    Wu Y; Yang L; Zhong L
    Atherosclerosis; 2010 Sep; 212(1):351-5. PubMed ID: 20594554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular bases of thioredoxin and thioredoxin reductase-mediated prooxidant actions of (-)-epigallocatechin-3-gallate.
    Zhang H; Cao D; Cui W; Ji M; Qian X; Zhong L
    Free Radic Biol Med; 2010 Dec; 49(12):2010-8. PubMed ID: 20951799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thioredoxin-1 and endothelial cell aging: role in cardiovascular diseases.
    Altschmied J; Haendeler J
    Antioxid Redox Signal; 2009 Jul; 11(7):1733-40. PubMed ID: 19187002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: possible therapeutic targets?
    Rochette L; Lorin J; Zeller M; Guilland JC; Lorgis L; Cottin Y; Vergely C
    Pharmacol Ther; 2013 Dec; 140(3):239-57. PubMed ID: 23859953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thioredoxin-1 is a novel and attractive therapeutic approach for various diseases including cardiovascular disorders.
    Billiet L; Rouis M
    Cardiovasc Hematol Disord Drug Targets; 2008 Dec; 8(4):293-6. PubMed ID: 19075641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Redox regulation by thioredoxin in cardiovascular diseases.
    Shioji K; Nakamura H; Masutani H; Yodoi J
    Antioxid Redox Signal; 2003 Dec; 5(6):795-802. PubMed ID: 14588153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thioredoxin reductase-thioredoxin fusion enzyme from Mycobacterium leprae: comparison with the separately expressed thioredoxin reductase.
    Wang PF; Marcinkeviciene J; Williams CH; Blanchard JS
    Biochemistry; 1998 Nov; 37(46):16378-89. PubMed ID: 9819230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The thioredoxin system as a therapeutic target in human health and disease.
    Mahmood DF; Abderrazak A; El Hadri K; Simmet T; Rouis M
    Antioxid Redox Signal; 2013 Oct; 19(11):1266-303. PubMed ID: 23244617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.